| Human immunodeficiency virus type 1 |
|
|
|
G-to-A |
APOBEC3C |
|
|
|
Contribute to viral diversity |
|
| Human immunodeficiency virus type 1 |
|
|
|
G-to-A |
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
G-to-A |
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
G-to-A |
APOBEC3 |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
G-to-A |
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
A-to-I |
APOBEC3 |
|
|
|
These mutation may preexist in proviral reser |
|
| Human immunodeficiency virus type 1 |
|
|
|
C-to-U |
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
G-to-A |
APOBEC3G |
|
|
|
No evidence supporting an impact of APOBEC3 a |
|
| Human immunodeficiency virus type 1 |
|
|
|
NA |
APOBEC3A |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
NA |
ADAR2 |
|
|
|
ADAR2 does not increase the infectious potent |
|
| Human immunodeficiency virus type 1 |
|
|
|
G-to-A |
APOBEC3H |
|
|
|
Slowing viral diversification; Escape from im |
|
| Human immunodeficiency virus type 1 |
|
|
|
NA |
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
NA |
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
NA |
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
ADAR1 |
|
|
|
The editing enzyme is incorporated into viral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3A |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3F |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3 |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
AID |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3A |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3A |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
ADAR1 |
|
|
|
Promote viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3H |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Prevents the formation of functional provirus |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Resulting in G to A hypermutation in the plus |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Association with the viral nucleoprotein comp |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Deaminase inhibition |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Not necessary for antiviral activity |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3F |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3F |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
Antiviral |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3F |
|
|
|
Inhibit viral replication |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
APOBEC3G |
|
|
|
not necessary for antiviral activity |
|
| Human immunodeficiency virus type 1 |
|
|
|
|
ADAR1 |
|
|
|
Stimulate viral infection |
|